

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUANCE OF 2023 PERPETUAL MEDIUM-TERM NOTES (TRANCHE 1) IN THE PRC BY CHINA UNIVERSAL LEASING CO., LTD., A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

As of the date of this announcement, China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the “**Issuer**”), a wholly-owned subsidiary of the Company, has registered with the National Association of Financial Market Institutional Investors (中國銀行間市場交易商協會) for the issuance of the domestic medium-term notes of an aggregate principal amount up to RMB1 billion in the People’s Republic of China (the “**PRC**”).

The Issuer has decided to launch the issuance of the first tranche of the domestic perpetual medium-term notes for year 2023 in the PRC with an aggregate principal amount of up to RMB250 million (the “T1 Notes”). The T1 Notes are with a term of 2+N years, and the T1 Notes will continue indefinitely until redemption by the Issuer, and will be due upon redemption by the Issuer in accordance with the terms of issuance. The T1 Notes will be attached with the extension option, deferred interest payment right and redemption option of the Issuer. During the first term (i.e. the first two years), the T1 Notes will have a fixed interest rate which will be determined at the end of the subscription period through book-building process . The coupon rate will be the aggregation of the initial benchmark interest rate and the initial interest rate spread. If the Issuer exercises the extension option, the coupon rate will be reset once in each term. The coupon rate for the subsequent term will be adjusted to the aggregation of the benchmark interest rate for such term, the initial interest rate spread, and 300 basis points. The net proceeds from the issuance of the T1 Notes will be used for repaying maturing debts of the Issuer.

The T1 Notes will be issued to domestic institutional investors in the PRC (other than those who are restricted from participating in such offering in accordance with the laws and regulations of the PRC). Postal Savings Bank of China Co., Ltd. (中國郵政儲蓄銀行股份有限公司) is the lead underwriter for the issuance of the T1 Notes, and Everbright Securities Company Limited (光大證券股份有限公司) and Bank of Tianjin Co., Ltd. (天津銀行股份有限公司) are the joint lead underwriters for the issuance of the T1 Notes.

Other principal terms of the T1 Notes to be issued are as follows:

Place of issuance:	The inter-bank bond market in the PRC
Par value:	RMB100.00
Issue price:	RMB100.00
Credit rating of the Issuer:	AAA rating for the Issuer
Trading arrangement:	The T1 Notes are expected to be traded on the inter-bank bond market in the PRC from 27 December 2023.

In accordance with the relevant laws and regulations in the PRC, relevant documents in relation to the Issuer and the T1 Notes will be published on the website of Shanghai Clearing House (<http://www.shclearing.com>) and China Foreign Exchange Trade System (www.chinamoney.com.cn), respectively. Shareholders of the Company and potential investors are reminded that such documents

were prepared in accordance with the requirements in the PRC and are limited solely to the Issuer, and the information contained therein does not provide a full picture of the operation status of the Company and its subsidiaries.

Further announcement(s) will be made by the Company in relation to the updated progress of issuance of the T1 Notes as and when appropriate.

By order of the Board
**Genertec Universal Medical Group Company
Limited**

通用環球醫療集團有限公司

Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 22 December 2023

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.